VEGFA and hepatocellular carcinoma: Most recently, the combination of monoclonal antibodies atezolizumab (anti-programmed death ligand-1; anti-PD-L1) and bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has shown, for the first time in any HCC clinical trial, superiority over sorafenib and is now FDA-approved as first-line treatment for advanced HCC (10).